Provided by Tiger Trade Technology Pte. Ltd.

Corgi U.S. Healthcare 2x Daily ETF

32.21
-0.2303-0.71%
Post-market: 31.49-0.7170-2.23%16:56 EDT
Volume:3K
Turnover:101.30K
Market Cap:644.14K
PE:- -
High:32.40
Open:32.40
Low:32.07
Close:32.44
52wk High:35.56
52wk Low:25.40
Shares:20.00K
Float Shares:20.00K
Volume Ratio:3.42
T/O Rate:15.72%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide

TIPRANKS
·
Yesterday

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

TIPRANKS
·
Sep 18

Ultragenyx confirms FDA approval of Fayuvi

TIPRANKS
·
Sep 18

Nuvation Bio announces FDA approval of sNDA for Ibtrozi

TIPRANKS
·
Sep 17

Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes

TIPRANKS
·
Sep 17

ASX biotech expands diagnostics portfolio after FDA approval

Morning Star AU
·
Sep 16

Barclays downgrades Scholar Rock on valuation after FDA approval

TIPRANKS
·
Sep 15

Biofrontera announces FDA approval of Ameluz supplemental new drug application

TIPRANKS
·
Sep 14

Scholar Rock Wins FDA Approval for SMA Therapy

TIPRANKS
·
Sep 14

Scholar Rock price target raised to $84 from $76 at BMO Capital

TIPRANKS
·
Sep 14

Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara

TIPRANKS
·
Sep 14

Scholar Rock announces FDA approval of isembyld

TIPRANKS
·
Sep 12

Pharming wins FDA nod to extend Joenja use to younger APDS children

TIPRANKS
·
Sep 12

Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them

Dow Jones
·
Sep 05

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

TIPRANKS
·
Sep 05

Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them

Dow Jones
·
Sep 04

Medicare Advantage Patients Who Get Diagnosed with Alzheimer's or Other Serious Diseases are Ditching Their Plans - and it Can Cost Them

Dow Jones
·
Sep 03

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

TIPRANKS
·
Aug 31

Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO

TIPRANKS
·
Aug 29

Takeda receives FDA approval of NDA for Mimrylo

TIPRANKS
·
Aug 29